Xifeng Qian

Xifeng Qian

Auto-generated profile, based on publicly available information

Xifeng Qian

Department of Cardiology, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in International Journal of Genomics
Verified
Journal Article
Open access
PDF file
XQXi-Feng Qian
Xi-Feng Qian
JZJia-Hao Zhang
Jia-Hao Zhang
YMYue-Xue Mai
Yue-Xue Mai
XYXin Yin
Xin Yin
YZYu-Bin Zheng
Yu-Bin Zheng
XGXu-Guang Guo
Xu-Guang Guo
Lower-grade gliomas (LGG) are the most common intracranial malignancies that readily evolve to high-grade gliomas and increase drug resistance. Paraptosis is defined as a nonapoptotic form of programmed cell death, which is gradually focused on patients with gliomas to develop treatment options. However, the specific role of paraptosis in LGG and its correlation is still vague. In this study, we first establish the novel paraptosis-based prognostic model for LGG patients. The relevant data of LGG patients were acquired from The Cancer Genome Atlas database, and we found that LGG patients could be divided into three different clusters based on paraptosis via consensus cluster analysis. Through least absolute shrinkage and selection operator regression analysis and multivariate Cox regression analysis, 10-paraptosis-related gene (PRG) signatures (CDK4, TNK2, DSTYK, CDKN3, CCR4, CASP9, HSPA5, RGR, LPAR1, and PDCD6IP) were identified to separate LGG patients into high- and low-risk subgroups successfully. The Kaplan–Meier analysis and time-dependent receiver-operating characteristic showed that the performances of predicting overall survival (OS) were dramatically high. The parallel results were reappeared and verified by using the Chinese Glioma Genome Atlas and Gene Expression Omnibus databases. Independent prognostic analysis and nomogram construction implied that risk scores could be considered the independent factor to predict OS. Enrichment analysis indicated that immune-related biological processes were generally enriched, and different immune statuses were highly infiltrated in high-risk group. We also confirmed the potential relationship of 10-PRG signatures and drug sensitivity of Food and Drug Administration–approved drugs. In summary, our findings provide a novel knowledge of paraptosis status and crucial direction to further explore the role of PRG signatures in LGG.

12 August 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
ZWZuoxiang Wang
Zuoxiang Wang
JLJunxing Lv
Junxing Lv
XQXifeng Qian
Xifeng Qian
ZLZiang Li
Ziang Li
ZYZheng Yin
Zheng Yin
YWYong-Jian Wu
Yong-Jian Wu
Background: Accumulating evidence indicates that degenerative valvular heart disease (VHD) and rheumatoid arthritis (RA) share overlapping risk factors and intersecting inflammatory processes; however, their interrelationship remains insufficiently explored. Methods: Among 492 745 UK Biobank participants without VHD at baseline, Cox proportional hazards models were conducted to assess the association between prevalent RA and new‐onset degenerative VHD, with sequential adjustments for demographic factors, lifestyle variables, and comorbidities. The end points of degenerative VHD in this study included 8 subtypes: aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid stenosis, tricuspid regurgitation, pulmonary stenosis, and pulmonary regurgitation. Results: Among participants with RA (n=6673), 359 cases of degenerative VHD were recorded over a median follow‐up of 13.71 (interquartile range, 12.71–14.55) years, compared with 13 518 cases in those without RA (n=486 072) over a median follow‐up of 13.78 (interquartile range, 12.96–14.51) years. After full adjustment, RA was significantly associated with a higher risk of 3 types of new‐onset degenerative VHD: aortic stenosis (hazard ratio [HR], 1.64 [95% CI, 1.40–1.92]), aortic regurgitation (HR, 1.69 [95% CI, 1.34–2.13]), and mitral regurgitation (HR, 1.54 [95% CI, 1.32–1.81]), while no significant association was observed between RA and other degenerative VHD subtypes. Moreover, sex subgroup analyses revealed an interaction between sex and RA in the occurrence of aortic stenosis ( P for interaction=0.02) and mitral regurgitation ( P for interaction=0.04), indicating a higher risk in women. Conclusions: The presence of RA indicated an elevated risk of new‐onset degenerative aortic stenosis, aortic regurgitation, and mitral regurgitation, which required further investigation and better disease management.

29 December 2017 in Gene
Verified
Journal Article
Closed access
SCSongyu Cao
Songyu Cao
JYJianshui Yang
Jianshui Yang
XQXifeng Qian
Xifeng Qian
Guangfu JinGuangfu Jin
Guangfu Jin
HMHongxia Ma
Hongxia Ma

19 August 2025 in Heart
Verified
Journal Article
Closed access
PDF file
ZWZuoxiang Wang
Zuoxiang Wang
XQXifeng Qian
Xifeng Qian
JLJunxing Lv
Junxing Lv
ZLZiang Li
Ziang Li
ZYZheng Yin
Zheng Yin
YWYong-Jian Wu
Yong-Jian Wu
Background Asthma has been associated with the development and progression of various cardiovascular diseases but its relationship with degenerative valvular heart disease (VHD) remains unclear. This study investigated the association between asthma and incident degenerative VHD, including aortic stenosis (AS), aortic regurgitation (AR), mitral regurgitation (MR) and pulmonary regurgitation (PR). Methods We analysed 483 735 participants from the UK Biobank (median age 56.5 years; 45.2% male) who were free of VHD at baseline. Asthma status was self-reported at recruitment. Incident VHD was ascertained through hospital admission and mortality records using International Classification of Diseases, Tenth Revision codes. Cox proportional hazards models were used to estimate HRs and 95% CIs for each VHD subtype, adjusting for demographic, lifestyle and clinical covariates. Sensitivity analyses accounted for asthma medications, duration of asthma and competing risks. Results Over a median follow-up of 13.8 years, 5388 participants developed AS, 2650 AR, 6088 MR and 821 PR. Asthma was associated with increased risk of AS (HR 1.31; 95% CI 1.21 to 1.41), AR (HR 1.24; 95% CI 1.11 to 1.39), MR (HR 1.19; 95% CI 1.10 to 1.28) and PR (HR 1.34; 95% CI 1.10 to 1.62). The association with AR was attenuated after adjusting for asthma medications (HR 1.12; 95% CI 0.97 to 1.30). Results were robust across multiple sensitivity analyses, including adjustment for asthma duration and exclusion of participants with pre-existing cardiovascular disease. Conclusions Asthma is independently associated with a modestly increased risk of several degenerative VHDs, particularly aortic and mitral valve diseases. These findings suggest a potential shared inflammatory pathway and highlight the need for heightened cardiovascular surveillance in individuals with asthma.